Clinical trials: Hyperphosphatemia
Chronic Kidney Diseases, Hyperphosphatemia
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: How much effect AP-306 has assessed by blood phosphorus lowering; How…
- Trial name
- NCT05764590
- Testing
- AP-306, Sevelamer Carbonate
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Alebund Pharmaceuticals
Hyperphosphatemia
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
- Trial name
- NCT04771780
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
The objective of this study is to investigate the safety and the effect on reduction of serum phosphate of long-term administration of lanthanum carbonate (BAY77-1931) 750 to 2250 mg in patients with hyperphosphatemia who…
- Trial name
- NCT01187628
- Testing
- Fosrenol (Lanthanum Carbonate, BAY77-1931)
- Where
- 40 sites in Japan
- Volunteers
- 123 people
- Sponsor
- Bayer
Hyperphosphatemia, End-stage Renal Disease
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD).
- Conditions
- Hyperphosphatemia, End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
- Trial name
- NCT00967993
- Testing
- ferric citrate
- Where
- 3 sites in Israel
- Volunteers
- 22 people
- Sponsor
- Keryx Biopharmaceuticals
Hyperphosphatemia
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
- Trial name
- NCT06664125
- Testing
- JMKX003002 will be administered orally, Sevelamer carbonate
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Jemincare
Chronic Kidney Disease, Hemodialysis
Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
Study hypothesis: Nicotinamide inhibits gastrointestinal phosphate absorption and serum phosphate levels of dialysis patients in a dose dependent manner.
- Conditions
- Chronic Kidney Disease, Hemodialysis, Hyperphosphatemia
- Trial name
- DONATO (NCT01200784)
- Testing
- Nicotinamide
- Where
- 36 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Hyperphosphatemia, End-Stage Renal Disease
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs.
- Trial name
- NCT01074125
- Testing
- ferric citrate
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 154 people
- Sponsor
- Keryx Biopharmaceuticals
Hyperphosphatemia
Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
To evaluate the effect and safety of KHK7791 to treat Hyperphosphatemia in ptatients on HD.
- Trial name
- NCT03864458
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 207 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Kidney Disease, Renal Dialysis
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.
- Conditions
- Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT00892749
- Testing
- ASP1585
- Where
- 4 sites in Japan
- Volunteers
- 248 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
This is a randomized, open-label study to evaluate different methods of initiating tenapanor therapy in CKD patients on dialysis with hyperphosphatemia, when they are either phosphate binder naïve or on phosphate binder therapy.
- Trial name
- OPTIMIZE (NCT04549597)
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- Ardelyx
Hyperphosphatemia, Chronic Kidney Disease
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
To evaluate the superiority to placebo, dose-responsibility and safety.
- Trial name
- NCT00505037
- Testing
- ASP1585, Sevelamer hydrochloride
- Where
- 6 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease, Hyperphosphatemia
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
Approximately 207 hyperphosphatemic CKD patients not on dialysis will be entered into this study at approximately 50 sites within approximately 9 European countries.
- Trial name
- ASPIRE (NCT00833768)
- Testing
- Sevelamer carbonate
- Where
- 36 sites in Austria, France and 7 more
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Hyperphosphatemia
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
- Trial name
- NCT06206135
- Testing
- the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
- Where
- South Korea
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- LG Chem
Chronic Renal Failure
Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
To evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01903213
- Testing
- bixalomer
- Where
- 8 sites in Japan
- Volunteers
- 123 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia
A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
To evaluate the effect and safety of a switch from phosphate binders to KHK7791 to treat Hyperphosphatemia in patients on HD.
- Trial name
- NCT03831607
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 67 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia, End Stage Renal Disease
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
To evaluate the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT03984760
- Testing
- Ferric Citrate, Sevelamer Carbonate
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Panion & BF Biotech Inc.